Zoetis Inc. (NYSE: ZTS) has launched Lenivia (izenivetmab injection), a monoclonal antibody therapy for osteoarthritis pain in dogs, in Canada and European Union member states, according to a company press release.

Lenivia is administered as a single subcutaneous injection once every three months. The therapy targets nerve growth factor, a mediator of pain and inflammation. Zoetis states the drug binds to a different site on nerve growth factor compared to other anti-NGF monoclonal antibodies already on the market.

A nine-month European field study cited by the company showed a sustained reduction in pain, with effects observed from as early as seven days after the first injection.

Lenivia is contraindicated in dogs with known hypersensitivity to izenivetmab, and in breeding, pregnant, or lactating dogs, as well as dogs under 12 months of age. The most common side effect listed in the EU product label is immediate pain upon injection, reported in 1 to 10 dogs per 100 treated. Uncommon side effects include ataxia, increased thirst, and increased urination.

The new product joins Zoetis' existing canine osteoarthritis portfolio, which includes Rimadyl (carprofen), Trocoxil (mavacoxib), and Librela (bedinvetmab).

"Osteoarthritis affects millions of dogs across Europe and Canada, and for many pet owners, watching their companion struggle with pain, reduced mobility and lower quality of life is deeply personal," said Jamie Brannan, Executive Vice President and Chief Commercial Officer of Zoetis. "A longer dosing interval can help free up capacity in the practice while offering pet owners greater convenience and improved compliance for the dog."

Studies referenced in the release indicate that up to 40% of dogs may have radiographic osteoarthritis, a chronic and progressive condition.